Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors

Molecular Pharmacology

Volumn 62, Issue 6, 2002, Pages 1492-1505

  Lazareno, S ^a   Popham, A ^a   Birdsall, N J M ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ETHYNYL 17BETA HYDROXY 5ALPHA ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; 17BETA HYDROXY 17ALPHA DELTA4 ANDROSTANO[3,2 B]PYRIDO[2,3 B]INDOLE; 17BETA HYDROXY 17ALPHA ETHYNYL DELTA4 ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; ACETYLCHOLINE; GALLAMINE; KT 5720; METHYLSCOPOLAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR; PG 987; RECEPTOR SUBTYPE; STAUROSPORINE; STRYCHNINE; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; WIN 62577;

ALLOSTERISM; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DISSOCIATION; DRUG RECEPTOR BINDING; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ALLOSTERIC REGULATION; ANDROSTANES; ANDROSTENES; ANIMALS; BENZIMIDAZOLES; CHO CELLS; CRICETINAE; LIGANDS; RADIOLIGAND ASSAY; RECEPTORS, MUSCARINIC;

EID: 0036892882     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.6.1492     Document Type: Article

References (32)

1. Bajwa JS and Sykes PJ (1979) Synthesis and structure of some azolo[a]pyrimidines, 2,6,7,8-tetrahydro-1H-cyclopenta[e]azolo[a]pyrimidines, 6,7-dihydro-5H-cyclopenta[f]-azolo[a]pyrimidines, 7,8-dihydro-6H-cyclopenta[f]-s-triazolo[4,3-b]pyridazine, 5,6,7,8-tetrahydro-azolo[b]quinazolines, 6,7,8,9-tetrahydro-azolo[a]quinazolines and 7,8,9,10-tetrahydro-s-triazolo[3,4-a]phthalazine. J Chem Soc Perkin Trans 13:3085-3094.
2. Bajwa JS and Sykes PJ (1980a) New steroidal heterocycles: Androstano[3,2-b](pyrimido[1,2-a]benzimidazoles. J Chem Soc Perkin Trans I 4:1859-1861.
3. Bajwa JS and Sykes PJ (1980b) New Steroidal Heterocycles: The Synthesis and Structure of Androsteno[2,3-g]-, androstano[3,2-f]- and androsteno[16,17-g]-pyrazolo[1,5-a]-pyrimidines. J Chem Soc Perkin Trans I 14:481-486.
4. Barlow RB and Tubby JH (1974) Actions of some esters of 3,3-dimethylbutan-1-ol (the carbon analogue of choline) on the guinea-pig ileum. Br J Pharmacol 51:95-100.
5. Birdsall B, Burgen ASV, and Roberts GCK (1980) Effects of coenzyme analogues on the binding of p-aminobenzoyl-L-glutamate and 2,4-diaminopyrimidine to Lactobacillus casei dihydrofolate reductase. Biochemistry 19:3732-3737.
6. Birdsall B, Burgen ASV, Rodrigues de Miranda J, and Roberts GCK (1978) Cooperativity in ligand binding to dihydrofolate reductase. Biochemistry 17:2102-2110.
7. Birdsall NJM, Farries T, Gharagozloo P, Kobayashi S, Lazareno S, and Sugimoto M (1999) Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: Functional studies. Mol Pharmacol 55:778-786.
8. Buckley NJ, Bonner TI, Buckley CM, and Brann MR (1989) Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 Cells. Mol Pharmacol 35:469-476.
9. Caulfield MP and Birdsall NJM (1998) International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50:279-290.
10. Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery. Nat Rev Drug Discov 1:198-210.
11. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
12. Christopoulos A, Lanzafame A, and Mitchelson F (1998) Allosteric interactions at muscarinic cholinoceptors. Clin Exp Pharmacol Physiol 25:185-194.
13. De Araujo JE, Huston JP, and Brandao ML (2001) Opposite effects of Substance P fragments C (anxiogenic) and N (anxiolytic) injected into dorsal periaqueductal gray. Eur J Pharmacol 432:43-51.
14. Ellis J (1997) Allosteric binding sites on muscarinic receptors. Drug Dev Res 40:193-204.
15. Ellis J and Seidenberg M (1992) Two allosteric modulators interact at a common site on cardiac muscarinic receptors. Mol Pharmacol 42:638-641.
16. Ellis J and Seidenberg M (2000) Interactions of alcuronium, TMB-8, and other allosteric ligands with muscarinic acetylcholine receptors: Studies with chimeric receptors. Mol Pharmacol 58:1451-1460.
17. 3H] acetylcholine to M2 muscarinic receptors. Biochem Pharmacol 52:1767-1775.
18. Holzgrabe U and Mohr K (1998) Allosteric modulators of ligand binding to muscarinic acetylcholine receptors. Drug Discov Today 3:214-222.
19. Lazareno S and Birdsall NJM (1993) Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations. Br J Pharmacol 109:1110-1119.
20. Lazareno S and Birdsall NJM (1995) Detection, quantitation and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: Interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378.
21. Lazareno S, Gharagozloo P, Kuonen D, Popham A, and Birdsall NJM (1998) Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: Radioligand binding studies. Mol Pharmacol 53:573-589.
22. 3H]scopolamine and acetylcholine at muscarinic receptor subtypes: Identification of a second allosteric site. Mol Pharmacol 58:194-207.
23. 2α-adrenergic receptor. Mol Pharmacol 53:916-925.
24. 1A adrenergic receptor. Mol Pharmacol 57:436-445.
25. Nikolaus S, Huston JP, and Hasenohrl RU (1999) Reinforcing effects of neurokinin substance P in the ventral pallidum: Mediation by the tachykinin NK1 receptor. Eur J Pharmacol 370:93-99.
26. Proska J and Tucek S (1995) Competition between positive and negative allosteric effectors on muscarinic receptors. Mol Pharmacol 48:696-702.
27. Sachais BS and Krause JE (1994) Both extracellular and transmembrane residues contribute to the species selectivity of the neurokinin-1 receptor antagonist WIN 51708. Mol Pharmacol 46:122-128.
28. Tränkle C and Mohr K (1997) Divergent modes of action among cationic allosteric modulators of muscarinic M2 receptors. Mol Pharmacol 51:674-682.
29. Ukai M, Shinkai N, Ohashi K, and Kameyama T (1995) Substance P markedly ameliorates scopolamine-induced impairment of spontaneous alternation performance in the mouse. Brain Res 673:335-338.
30. Venepalli BR, Aimone LD, Appell KC, Bell MR, Dority JA, Goswami R, Hall PL, Kumar V, Lawrence KB, and Logan ME (1992) Synthesis and substance P receptor binding activity of androstano[3,2-b]pyrimido[1,2-a]benzimidazoles. J Med Chem 35:374-378.
31. Waelbroeck M (1994) Identification of drugs competing with D-tubocurarine for an allosteric site on cardiac musearinic receptors. Mol Pharmacol 46:685-692.
32. Waelbroeck M, Hou X, Wehrle J, Mutschler E, Van Tilburg E, Menge W, Timmerman H, and Lambrecht G (1996) Stereoselective interaction of uncharged esters at four muscarinic receptor subtypes. Eur J Pharmacol 303:221-226.